ScholarIQanswers from OpenAlex & ORCID
Jen‐Shi Chen
ResearcherPublications, citations & collaboration network
Jen‐Shi Chen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jen‐Shi Chen have?
ScholarIQindexed works
Jen‐Shi Chen has 308 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jen‐Shi Chen have?
ScholarIQcitation count
Jen‐Shi Chen has 26,146 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jen‐Shi Chen?
ScholarIQh-index
Jen‐Shi Chen has an h-index of 45 in OpenAlex.
What is the i10-index of Jen‐Shi Chen?
ScholarIQi10-index
Jen‐Shi Chen has an i10-index of 196 in OpenAlex.
What is the ORCID of Jen‐Shi Chen?
ScholarIQorcid
The ORCID for Jen‐Shi Chen is on the source record.
What is the OpenAlex record for Jen‐Shi Chen?
ScholarIQopenalex
The OpenAlex for Jen‐Shi Chen is on the source record.
What are the most-cited papers on Jen‐Shi Chen?
ScholarIQmost cited works
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul, Yung‐Jue Bang, Ivan Borbath, Catherine Lombard‐Bohas, Juan W. Valle, Peter Metrakos, Denis Smith, Aaron I. Vinik, Jen‐Shi Chen, Dieter Hörsch, Pascal Hammel, Bertram Wiedenmann, Eric Van Cutsem, Shem Patyna, Dongrui R. Lu, C. Blanckmeister, Richard C. Chao, Philippe Ruszniewski
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz‐Josef Klümpen, Stephen L. Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W. Valle, Li Yu, Usha Malhotra, Abby B. Siegel, Julien Edeline, Arndt Vogel, Arndt Vogel, Mehmet Akce, Inmaculada Alés Díaz, Gustavo R. Alves, Sumitra Anand, Çağatay Arslan, Jamil Asselah, Eric Assenat, F. Aubin, Li‐Yuan Bai, Yuxian Bai, Olga Barajas, Susan E. Bates, Stephen Begbie, Irit Ben‐Aharon, Nina Beri, Marie‐Luise Berres, Jean‐Frédéric Blanc, Ivan Borbath, Robert Bordonaro, Mohamed Bouattour, Giovanni Brandi, Adam M. Burgoyne, Kritiya Butthongkomvong, Marcos Pedro Guedes Camandaroba, Ke Cao, Marcela Carballido, Jen‐Shi Chen, Jen‐Shi Chen, Ming-Huang Chen, Ashley Cheng, Ashley Cheng, Tai‐Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joëlle Collignon, Antonio Cubillo Gracián, S. Lindsey Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith de Vos, Maria Diab, Jacob C. Easaw, Martin Eatock, Julien Edeline, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernández, Richard Finn, Fábio Franke, Masayuki Furukawa, Junji Furuse, Olumide B. Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Oliver Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gümüş, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoğlu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Jun‐Eul Hwang, Mevlüde İnanç, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jiménez Fonseca, Warren Joubert
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao, T Shimamura, Masayuki Sho, Masayuki Kitano, Ann‐Lii Cheng, Kazuhiro Mizumoto, Jen‐Shi Chen, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Satō, Yasuo Ohashi, Takuji Okusaka, Masao Tanaka